Evoke Pharma, Inc.
The company, Evoke Pharma, focuses on developing and commercializing drugs for gastroenterological disorders. It offers Gimoti, a metoclopramide nasal spray for diabetic gastroparesis symptoms. Products are marketed to gastroenterologists, internal medicine specialists, primary care physicians, and select healthcare providers. The company was incorporated in 2007. Headquartered in Solana Beach, California.
Overview
Strengths
- Price to book ratio (1.09) is lower than the sector mean (733.70).
- EV/EBITDA (0.16) is lower than the sector mean (51.86).
- EV/EBIT (0.16) is lower than the sector mean.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 1.7 |